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ABSTRACT
Idiopathic intracranial hypertension (IIH) is a rare but
important disease associated with signiﬁcant morbidity.
There is an expected rise in prevalence in line with the
escalating global burden of obesity. Modern revisions in
the terminology and diagnostic criteria for IIH help guide
clinicians in investigations and researchers in
standardising recruitment criteria for clinical trials. The
pathophysiology of IIH is incompletely characterised;
suggested underpinning mechanisms include the role of
cerebrospinal ﬂuid regulation as well as metabolic and
endocrinological perspectives. Recent treatment trials are
providing insights into the management but debate still
surrounds key areas in treatment. This review will
provide an up-to-date discussion on the potential
pathogenic mechanisms and management of IIH.
INTRODUCTION
Idiopathic intracranial hypertension (IIH) is charac-
terised by raised intracranial pressure (ICP) of
unknown cause, when all other causes of raised
ICP have been excluded.1 IIH causes signiﬁcant
morbidity, including permanent visual loss in up to
25% of cases2 with reports of 1–2% of new cases
being registered blind per year3 and disabling head-
ache in the majority.4 With peak presentation being
between ages 20 and 40 years5; an overwhelming
female predominance and a strong association with
obesity5; IIH, is well known as a disorder that
affects overweight women of reproductive age.
There are a number of indicators that incidence
and prevalence of IIH are rising, likely related to
increasing prevalence of obesity worldwide; WHO
indicates a twofold increase in the UK between
1997 and 2002 and a threefold increase in the USA
between 1990 and 2006. A recent epidemiology
study reported an incidence of IIH occurring in 28/
100 000/year,6 which is the highest reported rate in
the literature so far.7 In the USA, there was a 320%
increase in new cerebrospinal ﬂuid (CSF) shunt
procedures for IIH between 1998 and 2002.8 IIH
is an expensive condition for society and the indi-
vidual: in the USA, total economic costs are esti-
mated at greater than US$444 million per annum,
and 57% of patients report signiﬁcant lost earnings
with 31% changing occupation.9
The aetiology and pathology are not fully estab-
lished, and the disorder has become the subject of
increasing scientiﬁc scrutiny over the last decade.
With no single cause implicated, uncertainties sur-
round the best therapeutics which have led to dif-
fering management strategies. Both adults and
children can be affected by IIH, however, paediatric
IIH may have different pathogenesis and clinical
course10 and is not discussed in this article. In this
review, we review adult onset IIH with focus on
the latest developments in both the pathogenic
mechanisms and management.
EPIDEMIOLOGY
The incidence and prevalence of IIH depend on
the geographical location of the population
studied; Andrews et al7 highlighted the diversity in
the worldwide epidemiology for IIH and cautioned
against comparing the rates because of inconsistent
deﬁnitions of obesity used in various studies.
Evidence from the literature suggests an incidence
between 1 and 3/100 000/year in the general popu-
lation. When stratiﬁed for reproductive age, female
gender and weight, the incidence rises by 12–28/
100 000/year.5–7 11
TERMINOLOGY
The nomenclature and diagnostic criteria used to
describe this condition have evolved over time. The
ﬁrst case of IIH, then termed serous meningitis,
was probably reported in the 1890s by Henrich
Quincke, a German physician, when lumbar punc-
ture (LP) was ﬁrst introduced. Nonne11 12described
a series of cases, similar to Dandy,13 of raised ICP
without tumour termed pseudotumour cerebri.
Both series contained cases that we now recognise
as raised ICP secondary to a known aetiology. The
maturing nomenclature and diagnostic criteria have
reﬂected the advances in investigating patients, par-
ticularly neuroimaging and understanding of
normal CSF opening pressure measurements, and
our increasing appreciation of the clinical course of
the disease. Some patients have a mild and self-
limiting course, while others experience substantial
morbidity from visual loss and persistent headache.
PATHOPHYSIOLOGY
The underlying pathogenesis of IIH is uncertain.
Raised ICP is a uniform characteristic, but the
mechanism by which ICP is elevated in IIH is not
clear. It is also questionable whether a single unify-
ing mechanism elevates ICP in these individuals
(ﬁgure 1). Secondary causative factors which lead
to elevation of ICP may be mechanistically distinct
from truly idiopathic causes.
Role of altered CSF dynamics
Changes in the volume of blood, CSF and brain
tissue inﬂuence ICP. IIH likely represents a disorder
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of CSF regulation, potentially through CSF hypersecretion or
reduced drainage.
Increased CSF production
The choroid plexus is the primary site of CSF secretion, gener-
ating around two-thirds of the total CSF produced, with the
rest coming from extrachoroidal sources, such as the ependyma
and possibly the blood brain barrier.14 15 In the choroid plexus,
CSF production is governed by a number of ion transporters
located on the choroid plexus epithelial cells. The net move-
ment of ions across these cells results in the movement of water
and, thereby, secretion of CSF. Increases in CSF production may
be attributed to an increase in choroid plexus size, or increased
activity of the choroid plexus. Macroscopically, patients with
IIH do not show any hypertrophy of the choroid plexus.
Additionally, CSF overproduction has only been demonstrated
in cases of choroid plexus papilloma and villous hyperplasia of
the choroid plexus, which all produce hydrocephalus.
Ventricular size is not altered in IIH, making CSF hypersecre-
tion unlikely. Infusion studies can provide an indicator of CSF
secretion. However, there are few studies in this area, and the
results are inconsistent.16
Dysregulation of ﬂuid transport in IIH may be important.
The water transporting channel, aquaporin 4, is localised to the
astrocyte foot process, and has a role in ﬂuid transport predom-
inantly relating to cerebral oedema. Anti-aquaporin 4 antibodies
have not been identiﬁed in IIH,17 and there is no evidence of
upregulation of the aquaporin 4 gene.18 Aquaporin 1 is another
candidate as these channels are predominantly in the choroid
plexus, can be upregulated by retinoids and glucocorticoids, and
are affected by medications used to treat IIH.
Reduced CSF drainage
Historically, it was believed that CSF drains from the subarach-
noid space through arachnoid granulations into the superior
sagittal sinus. However, evidence of CSF drainage through the
cranial nerves, and the cribriform plate into the lymphatics, has
been demonstrated in various species, including humans, using
microﬁl injections.19 Recently in mice, lymphatic vessels have
been discovered lining the dural sinuses which are then able to
drain CSF into the deep cervical lymph nodes.20 This latest
research disputes the long-held belief that the central nervous
system lacks a lymphatic system. In addition, the newly named
‘glymphatic pathway’ suggests that there is an exchange in ﬂuid
between the CSF in the subarachnoid space and the interstitial
ﬂuid in the brain along paravascular routes (ﬁgure 1).21
Arachnoid granulation agenesis in children does not always
result in elevated CSF, indicating that alternative CSF drainage
pathways are functioning. There is very limited understanding
of the role of lymphatic and glymphatic drainage in IIH, but
these pathways may well be highly relevant.
A reduction in CSF absorption by the arachnoid granulations
may be attributed to either an increase in CSF outﬂow resist-
ance, or a reduction in the pressure gradient between the
Figure 1 Schematic diagram of the possible pathophysiological mechanisms in idiopathic intracranial hypertension (IIH). Cerebrospinal ﬂuid (CSF)
is produced mainly by the choroid plexus epithelial cells, with a small amount being secreted by ependymal cells that line the ventricular system.
Classically, CSF was thought to drain predominantly through the subarachnoid space through arachnoid granulations into the superior sagittal sinus.
Evidence also suggests CSF drains through the cribriform plate along cranial nerves into the nasal lymphatics (yellow). The most recent hypothesis
proposes bulk ﬂow of ﬂuid along perivascular routes (glymphatic pathway) which is cleared from the brain into the subarachnoid CSF, bloodstream
or cervical lymphatics. Supporting this concept is the recent discovery of lymphatic vessels (yellow) in the dura that drain into the deep cervical
lymph nodes.
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subarachnoid space and the superior sagittal sinus. Increased
CSF outﬂow resistance has been demonstrated to lead to ele-
vated ICP, as seen in posthaemorrhagic hydrocephalus, where
blockage of the arachnoid granulation and lymphatics by blood
cells or ﬁbrosis is noted.22 Through a similar mechanism, both
CSF hypercellularity, as seen in malignant meningitis, and high
CSF protein, in Guillian-Barré syndrome, can elevate ICP.
Vitamin A deﬁciency can also lead to elevated ICP with evi-
dence of thickening of the extracellular matrix in the arachnoid
villi.21 Reduced CSF absorption has also been demonstrated in
patients with IIH through isotope methods designed to evaluate
CSF circulation and absorption.23
Role of obesity
Obesity is a consistent risk factor for the development of IIH.
Correlations between body mass index (BMI) and risk of IIH
have been demonstrated,24 as have associations between increase
in weight and disease recurrence.25 Conversely, weight reduc-
tion has been observed to improve vision.26 This was conﬁrmed
in a prospective cohort study using a low-calorie meal replace-
ment to induce weight loss, generating improvements in ICP
and papilloedema, as well as symptomatic improvements in
headache.27
Despite the association between IIH and an obese phenotype,
the pathological mechanisms tying the two together are unclear,
and IIH is a rare disorder, while obesity is common. Suggestions
that centrally distributed adiposity transmits pressure, thereby
generating raised ICP, are questionable, as few obese patients
have elevated ICP. Additionally, studies of waist:hip ratios in
patients with IIH suggest that adiposity is predominantly in the
lower body in IIH patients, by contrast with central adiposity of
typical obesity.28 A number of studies have evaluated cytokine
and adipokines proﬁles in the serum and CSF of patients with
IIH, but have been limited by small numbers and suboptimal
control groups. Results have not been consistent, which may
also be related to differences in the sensitivity of the assays used.
Leptin, an adipokine which regulates satiety at the hypothal-
amus, was elevated in the serum in one study, but this effect was
absent when BMI was controlled for.29 30 CSF leptin levels
appear elevated in IIH compared with controls matched for
BMI, age and gender. However, it remains to be established
whether dysregulation of adipokines and cytokines are patho-
genic in dysregulating ICP, or merely reﬂect a consequence of
the disease.
Retinol (a vitamin A derivative) has also been implicated in
IIH. Arctic explorers developed elevated ICP following excessive
ingestion of vitamin A rich polar bear liver.31 Levels of retinol
and retinol-binding protein have been evaluated in the serum
and CSF of patients with IIH, with results of both elevated and
decreased levels.32 33
Role of gender
A number of case reports have documented patients developing
raised ICP in the setting of endocrinopathies and with steroid
use (typically corticosteroid withdrawal). Intracranial hyperten-
sion in women using hormonal contraception and during preg-
nancy has been reported but is unsubstantiated, as many of
these cases have occurred in women with other risk factors for
IIH.34 Few studies have systematically evaluated the hormone
proﬁles in IIH. Early studies demonstrating elevated serum oes-
trone levels were compromised by small numbers and mixed
gender cohorts.35 A study using radioimmune assays to evaluate
cortisol, testosterone, bioavailable testosterone, prolactin, dehy-
droepiandrosterone sulfate, androstenedione, insulin,
aldosterone, oestradiol, follicle stimulating hormone and lutein-
ising hormone, demonstrated that younger patients with IIH
had elevated testosterone and androstenedione but a control
cohort was not evaluated.36
In the ocular ciliary epithelium 11 β-hydroxysteroid dehydro-
genase type 1 (11B-HSD1) drives secretion of aqueous humour
and 11B-HSD1 inhibitors reduce intraocular pressure.37 The
ciliary epithelium and the choroid plexus originate from a
similar embryological foundation and share secretory mechan-
isms. In rabbit and human choroid plexus, a functional
11B-HSD1 pathway has been identiﬁed, suggesting a potential
role in CSF secretion. In patients with IIH, following therapy
with a low-calorie diet, ICP falls in correlation with a reduction
in 11B-HSD1 activity.38
11B-HSD1 is also dysregulated in obesity and the metabolic
syndrome and consequently speciﬁc inhibitors are being devel-
oped as novel therapies.
Anatomical inﬂuence
Improvements in brain venography imaging reveal that most
patients with IIH have anatomical abnormalities of the cerebral
venous sinus system.39 These include stenosis of the dominant
(ﬁgure 2) or both transverse sinuses. There are two recognised
morphological types of venous stenosis, and a combination of
both can occur in one patient. An extrinsic stenosis is described
as a smooth gradually narrowing tapered stenosis. In the intrin-
sic type, discrete obstructions within the sinus are seen, and
these are thought to be due to arachnoid granulations or ﬁbrous
septae.40 Reducing ICP has led to resolution of stenosis in some
patients, suggesting that the stenoses are a result of raised ICP
externally deforming the venous sinuses, and not a primarily
cause.41 Additionally, elevated venous sinus pressure in the
setting of venous sinus stenosis, may impair CSF drainage at the
arachnoid granulation tissue further exacerbating a cycle of
intracranial hypertension. This has led to the rational for trans-
verse sinus stenting. The degree of stenosis does not appear to
uniformly correlate with ICP or visual loss.39
CLINICAL FEATURES
Visual loss is the major morbidity in IIH. Historic hospital-based
series reported bilateral blindness in up to 10%.2 42 More
recently, a British Ophthalmological Surveillance Unit study pro-
spectively found 1–2% of newly diagnosed IIH cases become
blind annually in the UK.3 The majority of patients with papil-
loedema suffer some form of visual loss, as measured by formal
perimetry.42 In fulminant cases visual loss is profound, poten-
tially occurring rapidly over a matter of days.43
Headache is the most common presenting symptom of IIH,
which can be highly heterogeneous, often described as daily,
bilateral, frontal or retroocular. Features consistent with
migraine, including unilateral throbbing, with nausea and
photophobia are also reported.44 Back pain, neck pain and
radicular pain frequently occur.45
Other ophthalmic-related symptoms include transient visual
obscurations and diplopia.10 45 Transient visual obscurations
(TVO) are characterised by transient visual loss or greying out
of the vision, and are usually related to postural changes or
straining. They tend to last no longer than a minute, and occur
in one or both eyes. TVO are thought to be the result of disc
oedema causing transient ischaemia at the optic nerve head.
Diplopia occurs in one-third to two-thirds of patients with
IIH at presentation.2 It tends to be binocular and horizontal, as
a consequence of abducens nerve palsy, and can resolve with
normalisation of ICP. Monocular diplopia may occur in the
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presence of severe papilloedema as a result of macular oedema
or later due to epiretinal membrane formation.
Pulsatile tinnitus is common and may be unilateral or bilat-
eral.2 10 42 Other associated symptoms include mood disturb-
ance and impairments in memory and concentration.
DIAGNOSTIC CRITERIA
The diagnostic criteria continue to move from symptom-based
standards to more quantiﬁable criteria. The most recent pro-
posal by Friedman et al (table 1) reﬂects the more accepted LP
opening pressures (OP) of 25 cm CSF or greater in normal
weighted adults and 28 cm CSF or greater in children.1
They include MRI scan ﬁndings consistent with raised ICP
(ﬁgure 2). Additionally, they have recognised that IIH may
occur in the absence of symptoms of elevated ICP and rarely in
the absence of papilloedema, so-called IIH without papilloe-
dema (IIHWOP).
There are a number of identiﬁable causes that give rise to sec-
ondary intracranial hypertension such as anaemia, obstruction
to venous drainage and exposure to various pharmacological
agents, for example, tetracyclines, hypervitaminosis vitamin A
and retinoids (table 2). Neuroimaging, either MRI or CT or
MRI, must exclude hydrocephalus, structural lesions, abnormal
meningeal enhancement and cerebral venous sinus thrombosis.
Comorbidities
Polycystic ovarian syndrome (PCOS) is a chronic endocrine con-
dition characterised by menstrual irregularities, ovarian dysfunc-
tion, hyperandrogenism and hirsutism. The prevalence of PCOS
in women with IIH is reported to be as high as 39–57%,46 com-
pared to 7–18% in the general population. Similar to IIH,
PCOS is a disorder of women of childbearing age, associated
with obesity, high serum leptin levels and low-grade
inﬂammation.
Metabolic syndrome is a collection of risk factors including
abdominal obesity, insulin resistance, circulating hypertriglyceri-
daemia (dyslipidaemia) and hypertension that combined
increased the risk of developing type 2 diabetes mellitus and car-
diovascular and cerebrovascular disease. The obese phenotype
of patients with IIH suggests that these patients may be at risk
of metabolic syndrome, however, the evidence is limited.
Fasting insulin levels have been found to correlate with BMI in
IIH, as would be expected, but have not been compared with
obese controls.36
Figure 2 (A) MRI T1-weighted sagittal imaging demonstrating an empty sella (the pituitary gland has been ﬂattened against the wall of the sella).
(B) MRI T2-weighted axial image demonstrating ﬂattening of the posterior globes at the insertion of the optic nerves, protrusion of the optic nerve
head into the vitreous and increased ﬂuid in the optic nerve sheath complex bilaterally. (C) MRI T2-weighted axial image demonstrating tortuosity
(kinking) of the intraorbital optic nerve on the left with ﬂuid in the associated optic nerve sheath complex. (D) MR venography (posterior view)
demonstrating a longitudinal extensive left transverse sinus stenosis (extraluminal appearance).
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ASSESSMENT AND INVESTIGATIONS
When papilloedema is identiﬁed, it is critical to measure the
blood pressure to exclude malignant hypertension. All manda-
tory tests of visual function should be recorded, including visual
acuity, colour vision, pupil examination and a dilated eye exam-
ination to document the optic nerve head and macular ﬁndings
and exclude an ocular cause for bilateral disc swelling. Eye
movements should also be tested, as an esotropia at distance
may be the only sign of a partial sixth nerve palsy. With papil-
loedema, the visual acuity may be normal or near-normal, so
this measure alone is not predictive of the severity of the
disease. Formal visual ﬁelds using manual or automated perim-
etry are required. Papilloedema demonstrates a variety of visual
ﬁeld defects (ﬁgure 3) including enlargement of the blind spot,
inferonasal defects, as well as central, paracentral, arcuate and
altitudinal scotomas.2 42 42
Pseudopapilloedema must be distinguished from early papil-
loedema. Ocular ultrasound may be useful in differentiating
optic nerve oedema from drusen and measuring ﬂuid in the
optic nerve sheath. Additionally, the calciﬁcation in optic nerve
head drusen are readily seen on CT imaging, therefore, revisit-
ing imaging performed may be useful. However, we do not rec-
ommend drusen as an indication for CT scanning. Fundus
ﬂuorescein angiography can identify optic disc leakage in papil-
loedema, and is used occasionally.47
Features of papilloedema include initial hyperaemia of the
disc, blurring of the disc margins, elevation of the disc with a
periapillary halo, loss of spontaneous venous pulsation and
obscuration of major vessels (ﬁgure 3). In severe papilloedema,
retinal vessels crossing the disc margin and overlying the optic
disc are obscured by the oedematous nerve ﬁbre layer; retinal
haemorrhages and cotton wool spots may be present, serial
colour fundus photographs are useful in recording disc ﬁndings
and help document resolution.
Formal grading of papilloedema using the Frisén scale has been
shown to have a limited reproducibility with high intraobserver
and interobserver variability, and requires a senior level of expert-
ise.48 Quantiﬁcation of disc swelling using optical coherence tom-
ography (OCT) is an important development. OCT permits
high-resolution non-invasive cross-sectional imaging of the neuro-
sensory retina (ﬁgure 3). It is analogous to ultrasound imaging,
measuring light waves rather than sound.49 Measurement of the
following parameters: retinal nerve ﬁbre layer (RNFL) thickness;
total retinal thickness; optic nerve (ONH) volume; and retinal
ganglion cell layer thickness; for longitudinal monitoring of papil-
loedema is useful.50 Practically in IIH OCT measurements have
been shown to correlated with Frisén grade, but not clinical fea-
tures or visual dysfunction.50 However, RNFL thickness demon-
strates an indiscriminate ability to separate the resolution of
papilloedema from axonal loss in optic atrophy (as exampled in
ﬁgure 3).51 As the technology advances, for example enhanced
depth imaging and newer light sources, OCT will hopefully be
able to distinguish buried ONH drusen.
Brain imaging has a central role in excluding space-occupying
lesions, obstructive hydrocephalus and cerebral venous sinus
thrombosis once papilloedema has been diagnosed. Ideally, MRI
head and orbits with intravenous contrast and MR or CT venog-
raphy should be performed. Figure 2 shows commonly observed
radiological signs of raised ICP although none are pathogno-
monic of IIH.
Following brain imaging, LP is mandatory to record the CSF
opening pressure and exclude a secondary cause. It is performed
with the patient relaxed in the lateral decubitus position. The
procedure may be technically challenging in the obese popula-
tion, and occasionally ﬂuoroscopic guidance is required. CSF
from the diagnostic LP is sent for microscopy, measurement of
protein, glucose and, if indicated, cytology, culture and assess-
ment of xanthochromia. Serum should be sent simultaneously
for glucose, renal function and blood count to exclude anaemia.
Further practical advice on investigating IIH can be found in
Mollan et al.47
Management
The 2015 Cochrane review concluded that there is no current
consensus on the best management strategy for IIH.12 The two
key approaches in IIH are to preserve visual function, and to
reduce long-term headache disability. The treatments employed
depend largely on the patient’s level of visual function and rate
of progression. Accepted medical interventions range from
dietary therapy (eg, responsible and sustainable weight loss,
Table 1 Diagnostic criteria for idiopathic intracranial hypertension
(IIH) adapted from Friedman et al1
Diagnosis of IIH
Diagnosis of IIH without
papilloedema
Diagnosis of IIH is definite if the patient
fulfils A–E
A. Papilloedema.
B. Normal neurological examination
except for sixth cranial nerve
abnormalities.
C. Neuroimaging: Normal brain
parenchyma without evidence of
hydrocephalus, mass or structural
lesion, and no abnormal meningeal
enhancement on MRI, with and
without gadolinium, for typical
patients (female and obese), and
MRI, with and without gadolinium,
and magnetic resonance venography
for others; if MRI is unavailable or
contraindicated, contrast-enhanced
CT may be used.
D. Normal CSF composition.
E. Elevated lumbar puncture opening
pressure (≥250 mm CSF in adults) in
a properly performed lumbar
puncture.
In the absence of papilloedema, a
diagnosis of IIH can be made if B–E
are satisfied, and in addition the
patient has unilateral or bilateral
abducens nerve palsy.
In the absence of papilloedema or
sixth nerve palsy, a diagnosis of IIH
can be suggested but not made if
B–E are satisfied, and in addition at
least 3 of the following are present
on neuroimaging:
1. Empty sella.
2. Flattening of the posterior
aspect of the globe.
3. Distension of the perioptic
subarachnoid space with or
without a tortuous optic nerve.
4. Transverse venous sinus
stenosis.
(See figure 2: MRI findings in IIH)
The diagnosis of IIH is considered probable if A–D are met, but the cerebrospinal
fluid pressure is below 250 mm.
Table 2 Conditions that may cause intracranial hypertension
Pharmacological agents Systemic conditions
Antibiotics: tetracycline and
derivatives, vitamin A derivatives:
isotretinoin, all-trans-retinoic acid (for
acute promyelocytic leukaemia)
Hormonal agents: corticosteroid
withdrawal, growth hormone,
thyroxine replacement in children
Other agents: lithium, nalidixic acid,
rofecoib, cimetidine
Haematological: anaemia
Respiratory: obstructive sleep apnoea
Renal: renal failure
Endocrine: obesity, weight gain,
polycystic ovarian syndrome, Cushing’s
disease, Addison’s disease,
hypoparathyroidism
Genetic: turner syndrome
Autoimmune: systemic lupus
erythematosus
Nutritional: hypervitaminosis A
Venous: cerebral venous sinus
thrombosis, superior vena cava
obstruction, increased right-sided heart
pressure
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lifestyle modiﬁcation, low-salt diet) to medications and surgical
treatment.
Weight loss
Newborg51 was the ﬁrst to document diet as a treatment for
IIH. In her uncontrolled prospective case series, nine patients
were treated with a low-calorie rice diet with ﬂuid (750–
1250 mL/day) and sodium (<100 mg/day) restriction; the result-
ant weight loss (13–38%) was associated with improvement in
IIH symptoms and assessments of papilloedema. The association
between weight loss and improvement in papilloedema was
further supported by several retrospective case reviews.52 53
A low-salt diet is often recommended in IIH based on the
association with orthostatic oedema in women.54 However,
there is no direct evidence for the mechanism of action of salt
restriction in vivo to reduce ICP.
On the basis of small studies showed that reduction of body
weight by 6% was associated with improved visual function and
papilledema grade in IIH,32 52 weight loss was studied in a pro-
spectively designed cohort study.27 Patients with chronic IIH
were treated with a severely restricted calorie-controlled diet
(425 kcal/day) for 3 months following a 3-month observational
period; 44% of the patients took a stable dose of acetazolamide
during the study. Internal comparators prediet and postdiet
within the same patient demonstrated signiﬁcantly reduced ICP
measurements (−8 cm CSF, p<0.001), headache scores and
papilloedema. There was a 15% mean weight reduction
(p<0.001). All qualitative and quantitative improvements were
sustained at 3 months postdiet cessation. This study provided
evidence that weight loss can lower ICP.
Long-term maintenance of weight loss is notoriously difﬁcult
and is typically as little as 2–4 kg at 2 years, irrespective of the
dietary regime followed.55 In keeping with this, patients in the
Birmingham weight loss study27 were noted to regain weight in
the year following discontinuation in the study and, conse-
quently, their symptoms and signs of IIH relapsed, a documen-
ted phenomenon in IIH.25 42
Obesity pharmacological therapies, such as tetrahydrolipstatin
and phentermine/topiramate may induce a modest weight loss,
but have not been speciﬁcally studied in IIH.55 There is class IV
evidence for bariatric surgery as an effective treatment for IIH
in obese patients, both in terms of symptom resolution and
Figure 3 Comprises three patients (A–C). All have a composite of colour fundus photograph on left hand side. Spectral domain (SD) optical
coherence tomography (OCT) cross-section image through the optic nerve head, above. The extent on the retinal nerve ﬁbre layer is depicted
between the ﬁne red (internal limiting membrane (ILM)) and green lines in this grey scale image. SD-OCT retinal nerve ﬁber layer (RNFL) thickness
line graph showing RNFL thickness values, below. The ﬁne black line depicting the patient’s data, and the block colours (green, yellow, red)
showing the normative data. Humphrey visual ﬁeld 24-2 grey scale image on right. VFI, visual ﬁeld indicator; MD, mean deviation; PSD, pattern SD.
Patient A, a newly diagnosed patient with IIH, showing Frisen grade 3, there is obscuration of more than one major vessel leaving the disc, there is
a circumferential halo and elevation of all borders. Paton’s lines (curvilinear chorioretinal folds adjacent to the temporal (left hand side) of the optic
disc margin) are evident. Patient B, a newly diagnosed patient with IIH with Frisen grade 2 there is no major vessel obscured. Circumferential halo
and elevation of the nasal border only. Patient C, a treated patient with IIH who has resolved papilloedema (Frisen grade 0). There is reduction in
the RNFL thickness which is due to resolution of swelling, but also axonal loss. There is a centrocecal visual ﬁeld defect.
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visual outcome.55 A randomised control trial evaluating bariatric
surgery in IIH is currently underway (Clinical trials. gov ID
NCT02124486).
Pharmacotherapy
Acetazolamide
Acetazolamide is currently considered the mainstay of pharma-
cological management in IIH. It is a potent enzyme inhibitor of
carbonic anhydrase, and it impedes the activity at the choroid
plexus reducing CSF secretion. A recent Cochrane systematic
review identiﬁed two randomised control trials for the use of
acetazolamide in IIH.12
Ball et al57 in the UK, prospectively evaluated acetazolamide
use in mild IIH. Fifty patients were recruited and randomised to
receive acetazolamide (daily dose between 250 and 1500 mg) or
placebo. Symptoms, body weight, visual function and
quality-of-life measures were recorded. Regardless of treatment
allocation, all overweight patients were advised to follow a
weight reduction programme. There was no signiﬁcant differ-
ence between the treatment arms at the ﬁnal 12-month
follow-up evaluation; based on this study design, a sample size
of 320 would be required to demonstrate a 20% treatment
effect. Overall, most participants showed clinical improvement,
with 44% judged to be in remission at trial end. Mean weight
loss was 6.2 (5.8%) and 3.3 kg (3.5%) in the treatment arm and
control arm, respectively. They highlighted issues in conducting
a trial in IIH that included recruitment, choice of outcome mea-
sures and adherence to acetazolamide.
The Neuro-Ophthalmologic Research Disease Investigator
Consortium (NORDIC) enrolled 165 participants to the IIH
Treatment Trial (IIHTT).58 This was a multicentre, randomised,
double-masked, placebo-controlled trial designed to determine
the efﬁcacy of acetazolamide compared with placebo in IIH,
with both arms also receiving a supervised weight-reduction,
low sodium diet. The initial dosing of acetazolamide was
500 mg twice a day with a schedule to increase the dose by
250 mg every 6 days up to a maximum of 4 g daily. Participants
who could not tolerate the study drug could decrease the
dosage to a minimum of 125 mg/day. All participants received a
speciﬁc dietary plan and lifestyle modiﬁcation programme. The
primary outcome measure was the change in perimetric mean
deviation (PMD) on automated visual ﬁeld analysis at 6 months.
The study population included individuals with IIH and mild
visual ﬁeld loss, deﬁned as PMD of −2 to −7 dB in the worst
eye59 (ﬁgure 3 shows two patients (B and C) visual ﬁelds that
fall between −2 and −7 dB).
Both treatment groups in the IIHTT showed improvement in
the primary outcome measure of PMD from baseline (−3.53 dB
in both groups). At 6 months, the PMD in the acetazolamide
group had improved more than the placebo group (−2.10 dB
compared to −2.82 dB, a difference of 0.71 dB, p=0.05).
Signiﬁcant difference in improvements between the acetazola-
mide and placebo group was also reported for the fellow eye
PMD, Frisén papilloedema grade, CSF opening pressure and
quality-of-life measures including the Visual Function
Questionnaire-25 and its neuro-ophthalmic supplement. No sig-
niﬁcant difference between the groups was found in visual
acuity in the study or fellow eye, headache or headache
disability.
Both groups lost weight at 6 months from a baseline of
107.72 kg. Those receiving acetazolamide lost more weight
(−7.50 kg) than those receiving placebo (−3.45 kg), and this dif-
ference was highly signiﬁcant (p<0.001). The mean dose of
study drug in the acetazolamide group at conclusion of the
study was 2.5 g/day, which is in excess to what is normally pre-
scribed in routine UK clinical practice due to side effects.
Indeed, in the IIHTT, adverse effects of fatigue, nausea, diar-
rhoea, vomiting and paraesthesia were signiﬁcantly higher in the
acetazolamide group. There were 6 treatment failures in the
placebo group and only 1 in the acetazolamide group. 19% of
subjects withdrew from the study but the reasons and frequency
of withdrawal was similar in both groups. The IIHTT provides
class 1 evidence that acetazolamide use provides a modest
improvement in visual ﬁeld function in patients with IIH with
mild loss.
Topiramate
Topiramate alters several targets such as inhibition of voltage-
gated sodium and calcium channels, augmentation of
γ-aminobutyric acid (GABA)-induced chloride ﬂux, inhibition of
glutamate-related excitatory neurotransmission and action on
carbonic anhydrase isoenzymes. Topiramate use was ﬁrst
reported in a prospective open label study of 40 patients using
both topiramate (daily dose range 100–150 mg) and acetazola-
mide daily (dose range 1000–1500 mg)60; however, no placebo
group was included. A statistically signiﬁcant improvement in
visual ﬁeld was detected with both drugs, with no statistically
signiﬁcant difference found when compared with each other.
Weight loss was prominent in the topiramate group. The side
effect proﬁle is similar to acetazolamide, however, adverse cog-
nitive effects can occur, and the drug is not recommended for
use in patients with a history of severe depression. Additionally,
as topiramate is a ﬁrst-line agent for migraine prevention
(National Institute for Clinical Excellence Guideline CG150) it
may have additional beneﬁt for those patients with IIH with
coexisting migraine-like headaches (68% at diagnosis).44
Other drugs
Other diuretics, such as furosemide, are used in IIH, when acet-
azolamide is contraindicated or not tolerated. There is animal
evidence that furosemide reduces CSF production, possibly by a
different mechanism to acetazolamide, and it is postulated that
it might have an additive effect to acetazolamide.61 Caution is
advised when combining diurectics, as severe hypokalaemia may
result. Octreotide is a somatostatin analogue which inhibits pitu-
itary growth hormone (GH) secretion, and antagonises GH and
insulin-like growth factor action by blocking GH receptors.
Somatostatin receptors are highly expressed in arachnoid villi
and choroid plexus and, therefore, may be related to CSF pro-
duction and absorption. Following case reports, an unblinded,
open-label study reported resolution of papilloedema in 92% of
cases with further improvement in other visual parameters and
headache.62 Given the observational nature of this study, the
small study size, and the lack of a control group, further data
are required.
Non-medical interventions
If medical therapy fails, is not tolerated, or there is fulminant
IIH, more aggressive measures should be considered.
Management options include serial LP; optic nerve sheath fenes-
tration (ONSF); neurosurgery employing shunts and stenting of
the transverse venous sinuses. The decision regarding the choice
of surgical procedure often depends on local expertise and the
patient’s morbidity.
Lumbar puncture
Occasionally, a single LP may be all that is required to put IIH
into remission.63 Serial LP are useful temporising measures
Mollan SP, et al. J Neurol Neurosurg Psychiatry 2016;0:1–11. doi:10.1136/jnnp-2015-311302 7
General neurology
group.bmj.com on May 25, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
while awaiting surgery, or in pregnant patients who wish to
avoid medical therapy. LP may reverse transverse venous sinus
collapse by lowering CSF pressure, therefore, providing tempor-
ary relief until the sinus re-collapses, usually within weeks.
Complications include low-pressure headaches, CSF leak and
CSF infection.
Optic nerve sheath fenestration
ONSF aims to relieve raised CSF pressure in the subarachnoid
space surrounding the optic nerves by incision of the meninges
enclosing the optic nerve. It is regarded by some as the pre-
ferred option for patients with visual symptoms, particularly if
there is unilateral visual compromise. A recent meta analysis
included 712 patients who underwent ONSF: 59% had an
improvement in vision, 44% resolution of headache, and 80%
reduction in papilloedema.64 Complications included diplopia
and pupil abnormalities with permanent visual loss reported in
1–2% secondary to retinal vascular occlusion or traumatic optic
neuropathy. Unilateral ONSF has been reported to signiﬁcantly
improve papilloedema grade in both eyes. Repeat surgery was
required in 14.8% of patients, and over a third of patients
required subsequent CSF diversion.64
A comparative case series between ONSF and CSF diversion
showed both procedures resulted in improved visual acuity and
visual ﬁelds (using PMD) postsurgery, but CSF diversion
resulted in a statistically signiﬁcant improvement in PMD com-
pared to ONSF. Lack of randomisation and selection bias limit
the utility of this study.65
CSF diversion surgery
CSF diversion surgery was initially employed in 1949 using ven-
triculoperitoneal shunts, and by the 1970s, good outcomes were
reported with lumboperitoneal shunting (LPS). In LPS, a cath-
eter inserted into the subarachnoid space at the level of the
lumbar spine is then tunnelled under the skin, continuing
around the oblique muscles and into the peritoneal cavity where
the drained CSF is absorbed. Shunts with a valve system and
CSF reservoir are recommended as they reduce risk of signiﬁ-
cant pressure ﬂuctuations. Complications of CSF diversion
surgery include shunt infection, shunt obstruction,
intra-abdominal pain and CSF leak. Rarer complications include
cerebellar tonsillar herniation and syringomyelia, subdural and
subarachnoid haemorrhage, and bowel perforation. Shunt revi-
sions have been reported in 51% of patients and multiple revi-
sions required in 30%.66 Sinclair et al66 found signiﬁcant
improvements in visual acuity maintained postoperatively at 6
(p=0.002) and 12 months (p=0.016), but headache symptoms
persisting in the majority of patients at 12 months.
Transverse sinus stenting
Teleb et al67 reported the largest group analysis to date for the
endovascular management of IIH. The gradient threshold at
which the transverse sinus stentings (TSS) were performed
varied between ≥4 to ≥10 mm Hg. Antithrombotic therapy was
typically dual antiplatelet therapy (aspirin and clopidogrel).
Patients were pretreated and expected to remain on dual
therapy for up to 6 months, followed by aspirin for up to
12 months. Complications of the procedure include a short-
lived ipsilateral headache in many, restenosis and, in rare cases,
vessel perforation leading to acute subdural haematoma, stent
migration and thrombosis. TSS conferred functional improve-
ments in symptoms and signs including headache, papilloedema
grade and reported visual loss. There are currently major limita-
tions of evidence with case series being non-randomised, not
detailing morphological stenosis type, being small in size with
selection bias and a lack of long-term follow-up.68 At least one
death has been reported, with known cases of life-threatening
haemorrhage and herniation following stenting.
Treatment of headache
Headache is the most common presenting feature in IIH and
leads to signiﬁcant morbidity.69 Many patients do not have the
classical headache phenotype attributed to raised ICP and the
International Classiﬁcation of Headache Disorders, which does
not specify a particular headache phenotype (ICHD 3) has poor
speciﬁcity (53%) in IIH.70 Many patients with IIH have daily
headache (86%) that often resembles migraine or tension-type
headache. Other features from the history can be useful, but are
not pathognomonic, and can occur in both IIH and headache
control subjects (exacerbation with bending 50% and 44%,
respectively; morning headache 20% and 29%, respectively;
exacerbation with cough or Valsalva 70% and 35%, respect-
ively).70 IIH headache improves post-LP in 72%, but an
improvement also occurs in 25% of those with headache
without IIH or a pressure syndrome.70
Most headache improvement occurs during the ﬁrst month
following diagnosis and treatment with constant headaches in
64% at diagnosis improving to 13% by 1 month.44 Yet, 63%
continue to have headaches at 12 months, and headaches can
remain even after ICP has normalised in 67%. Headaches out-
comes are poor even in those with no prior history of headache,
with 57% having headaches at 12 months.44
There is little evidence to guide the management of headache
attributed to IIH. Accurate headache phenotyping is key, and
mixed headache types frequently coexist (high pressure,
migraine, tension-type, low pressure in those with a shunt).
Medication overuse headaches often occur and are
underdiagnosed.71
Our practice is to treat the predominant headache phenotype,
typically using migraine-preventative strategies. It is worthy of
note that some of the commonest medications here can cause
weight gain. An excellent review in this area covers these
options in detail.72 Shunting is generally ineffective manage-
ment strategy for raised ICP headaches, as 79% still have head-
aches at 2 years, low-pressure headaches may develop (28%),
and shunt failure is a major issue (>50% are revised).66 Weight
loss strategies signiﬁcantly improve headache.30 In the IIHTT,
headache disability improved in both treatment groups with no
beneﬁt of acetazolamide compared with placebo.58 As head-
aches have such a signiﬁcant impact on patients, management by
a headache medicine specialist is recommended.
Health-related quality of life
For patients with IIH, the journey is typically extremely challen-
ging. The diagnostic process with urgent brain imaging and LP
is frightening and painful. The ensuing discussion about the
causative role for obesity may be insensitively handled by the
busy physician and can be psychologically damaging for the
patients. For many, the reality is a long-term illness dominated
by drug side effects, headaches, potential depression and in
some surgery, which can be recurrent. The impact on their
family life, occupation and earning potential is great.
Studies verify that IIH has a signiﬁcant effect on health-related
quality of life (QOL)69 73 patients with IIH have also been found
to have higher levels of anxiety, depression and fatigue than con-
trols.74 In the IIHTT QOL scores were measured and found to
be reduced at the time of the IIH diagnosis.75 PMD in the best
eye, visual acuity in the worst eye, visual symptoms, and pain
8 Mollan SP, et al. J Neurol Neurosurg Psychiatry 2016;0:1–11. doi:10.1136/jnnp-2015-311302
General neurology
group.bmj.com on May 25, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
symptoms, but not obesity, were independently associated with
reduced QOL. QOL scores have been shown to improve with
weight loss alongside signiﬁcant improvement in clinical mea-
sures and headache, in IIH. In this study, headache disability was
the only clinical outcome that correlated with impaired QOL, a
ﬁnding also noted in other studies.73
Cognition
A number of factors could impact on cognitive function in IIH
(depression, headaches, sleep apnoea, obesity, medications and
raised ICP). One study reported reduced reaction time and pro-
cessing speed in patients with acute IIH compared with age and
gender-matched controls. These deﬁcits were maintained at a
3-month follow-up, despite improving headaches and ICP.75
Another cross-sectional study has also demonstrated multidomain
mild cognitive impairment in IIH, with lowest scores in visuo-
spatial, attention and global indices.76 Cognitive dysfunction may
contribute to the patient morbidity, however, it is largely uncertain
whether the deﬁcits are chronic or related to treatment effects.
IIH without papilloedema
In patients with chronic daily headache, raised CSF pressure has
been identiﬁed in some patients, particularly in the obese,
despite the lack of papilloedema. The chosen cut-off for
‘normal’ ICP is essential when considering the diagnosis of
IIHWOP. Earlier series using an LP pressure cut-off value of
20 cm CSF are likely to have led to overestimation of the
number of cases.77 Although, patients with IIWOP have been
found to have lower LP opening pressure than those with papil-
loedema (31 vs 37 cm CSF), are more likely to be
treatment-resistant, and have non-organic visual ﬁeld defects.78
The latest diagnostic criteria (table 1) have helped to establish
which patients may truly have raised ICP by specifying the need
for identiﬁcation of ancillary features of raised ICP (imaging fea-
tures and sixth cranial nerve palsies). Pulsatile tinnitus is a
feature of raised ICP and is more common in patients with IIH
than migraineurs, but can occur in both patient cohorts (64%
compared against 26%).70
Isolated, single LP measures are not ideal in assessing patients
with chronic headaches as ICP ﬂuctuates diurnally. In some
cases, a period of prolonged CSF monitoring, ideally while the
patient is ambulatory is helpful.79 Accurate diagnosis is essential
to ensure chronic migraine with a borderline-raised ICP are not
incorrectly labelled as having IIHWOP.
The absence of papilloedema, despite elevated ICP is intri-
guing and requires further evaluation. Anatomical variations in
the optic canal diameter are seen even within the same patient
leading to asymmetrical papilloedema which has been elegantly
illustrated by Bidot.80
As patients with IIHWOP do not have papilloedema and do
not develop papilloedema, they do not develop visual loss
(although functional visual ﬁeld constriction occurs in 20%).77
Consequently, visual monitoring is not necessary and manage-
ment should focus on the headache. Venous sinus stenoses have
been identiﬁed in these patients as would be consistent with a
raised pressure syndrome. However, the role of venous stenting
in this cohort is not established, particularly as venous sinus
stenosis can occur in healthy asymptomatic individuals, in
migraineurs and in asymptomatic individuals labelled with
IIHWOP.81
CONCLUSION
IIH is classiﬁed as a rare condition, and early diagnosis and
treatment are imperative to prevent permanent visual loss. The
burden on the health service is signiﬁcant and costly due to high
healthcare utilisation by patients. This is unlikely to improve in
the setting of growing global obesity ﬁgures. For clinicians man-
aging patients with IIH, questions remain about the optimal
evidence-based approach for management. The conundrum of
how obesity and female gender contribute to the underlying
aetiology remains. IIH is a multisystem disorder encompassing
neuroscience, ophthalmology and endocrinology and cross-
specialty collaboration will be integral to advance our under-
standing of IIH. In the clinical environment, multidisciplinary
input is essential to optimise patient care.
Recent research momentum has led to important progress in
our understanding and management of IIH. The ﬁeld continues
to advance with a number of ongoing trials (eg, IIH:WTevaluat-
ing weight loss strategies and bariatric surgery (NCT02124486),
and IIH:DT evaluating a novel 11β HSD1 inhibitor
(NCT02017444), stenting in refractory IIH (NCT02143258)),
and studies the NORDIC group evaluation of vitamin A and
genetics). The results of these studies are eagerly anticipated,
and will, hopefully, translate into improved patient care.
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